feedback

Course Director

Rebecca S. Heist, MD, MPH
Rebecca S. Heist, MD, MPH

Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Faculty

Jacob Sands
Jacob Sands, MD

Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Accredited by

Medical Learning Institute, Inc.

Activity Description

In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, pulmonologists, surgeons, interventional radiologists, advanced practice clinicians, nurses, pharmacists, and other healthcare professionals involved in precision testing and treatment of lung cancer.

Educational Objectives

Upon completion of this activity, participants will be able to:
  • Discuss the expanding role and increasing importance of broad genomic testing to identify molecular alterations that can guide the selection of matched targeted therapies for patients with NSCLC in the era of precision oncology
  • Describe new, emerging, and/or rare molecular alterations (eg, fusions, mutations, etc.) that are clinically relevant and therapeutically targetable in NSCLC, including NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others, and the latest testing methods/tools for identifying these alterations
  • Analyze data from clinical trials of precision therapies that target molecular alterations such as NTRK, RET, ROS1, and NRG1 fusions, MET and KRAS G12C mutations, HER2 mutations or overexpression, EGFR exon 20 insertions, and others in advanced NSCLC
  • Implement best practices and collaborative strategies for integration of wide-spread molecular testing and interpretation of results into oncology and pathology workflows in community and academic settings to ensure that appropriate patients with NSCLC with genomic alterations are identified and receive the most appropriate therapies in the context of clinical practice or clinical trials

Providership, Credit, and Support


This CME/MOC/CC/CNE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca, EMD Serono, Inc., Lilly, and Novartis Pharmaceuticals Corporation. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Physician Continuing Medical Education

ACCMEThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Certification Statement

The activity titled "It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC" has been registered to offer 1.0 Lifelong Learning (Part II) credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Continuing Nursing Education

ANCCMedical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.0 contact hour(s).

Continuing Pharmacy Education

ACPEThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: 0468-9999-20-015-H01-P
Type of Activity: Knowledge

Faculty Disclosures

Co-Chair
Rebecca S. Heist, MD, MPH
Thoracic Oncology, Massachusetts General Hospital Cancer Center
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Rebecca S. Heist, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Apollomics, Inc.; Boehringer Ingelheim GmbH; Novartis Pharmaceuticals Corporation; and Tarveda Therapeutics.
Grant/Research Support from AbbVie Inc.; Agios, Inc.; Corvus Pharmaceuticals ; Daiichi Sankyo, Inc.; Eli Lilly and Company; Exelixis, Inc.; Genentech, Inc.; Incyte; Mirati Therapeutics, Inc.; and Novartis Pharmaceuticals Corporation (Funding to institution).

Co-Chair
Jacob Sands, MD
Physician, Dana-Farber Cancer Institute
Instructor of Medicine, Harvard Medical School
Boston, Massachusetts

Jacob Sands, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim GmbH; Eli Lilly and Company; Foundation Medicine, Inc.; Jazz Pharmaceuticals, Inc.; Medtronic; and PharmaMar.

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Nurse Planner, MLI, has nothing to disclose.
Teresa Haile, RPh, MBA, Pharmacy Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewer has nothing to disclose:

Jim Zhai, MD, FCAP
Gina D. Cravey, BSN, RN, CHRC, CCRC
Patricia A. Ensor, RPh, MBA

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain MOC/CC/CNE credit. There are no prerequisites and there is no fee to participate in this activity or to receive MOC/CC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: mycpemonitor.net.

About This CME/MOC/CC/CNE/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.